Titan Pharmaceuticals, Inc. announced the appointment of two new members to its board of directors. Mr. Scott Smith, president of global inflammation and immunology at Celgene Corporation, and Dr. Rajinder Kumar, CEO of MeRaD Pharmaceutical Ltd., bring to Titan extensive product development and commercialization experience in the U.S., Europe and Asia. In his current role as president of global inflammation and immunology, Mr. Smith leads a team of over 1,300 people and is responsible for the inflammation and immunology portfolio, including all global commercial, clinical development, regulatory, medical affairs and finance activities. Prior to joining Celgene, Mr. Smith was vice president, general manager and head of strategic and business analysis at Biovail Pharmaceuticals Inc., where he managed commercial business units in the U.S. and Canada. Dr. Kumar is the founder, chairman and CEO of MeRaD Pharmaceutical in Cambridge, England Dr. Kumar held senior positions in big pharma, biotech and academia. Prior to founding MeRaD, he served in various executive capacities with Dr. Reddy's Labs, Ranbaxy Laboratories Limited, Synaptic Pharmaceutical LLP, Glaxo SmithKline, and SmithKline Beecham.